We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Neglected Tropical Skin Diseases Their Global Elimination Through Integrated Mass Drug Administration?

Peter J. Hotez, MD, PhD1; Rosannah M. Velasquez, BS2; John E. Wolf Jr, MD3
[+] Author Affiliations
1Sabin Vaccine Institute & Texas Children’s Hospital Center for Vaccine Development, Section of Pediatric Tropical Medicine, Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas
2National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas
3Department of Dermatology, Baylor College of Medicine, Houston, Texas
JAMA Dermatol. 2014;150(5):481-482. doi:10.1001/jamadermatol.2013.8759.
Text Size: A A A
Published online


In 2005, the concept of a combination of essential medicines—the “rapid-impact” package—was proposed to simultaneously target 7 high-prevalence neglected tropical diseases (NTDs) in sub-Saharan Africa through programs of annual mass drug administration.1 The approach relied on the observation that the major NTDs affecting the poorest people in sub-Saharan Africa, led by hookworm infection, ascariasis, schistosomiasis, trichuriasis, trachoma, lymphatic filariasis (LF), and onchocerciasis, have similarities in terms of their abilities to cause long-term disabilities and ultimately poverty by influencing worker productivity in the tropics and child development, as well as having effects on girls and women, especially during pregnancy. Moreover, these NTDs overlap geographically and therefore can be treated at roughly the same time through once-annual administration of an integrated package containing albendazole (or mebendazole), ivermectin, praziquantel, and azithromycin.1 Together, these medicines could be administered for less than US $1 annually, making this approach highly cost-effective.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Posted on June 16, 2014
Colin Crawford, MRCP
Conflict of Interest: None Declared

It is surprising that Professor Hotez and colleagues (1) do not mention leprosy, which is a neglected tropical disease, in their discussion of skin disorders. Moreover, mass treatment campaigns, using dapsone monotherapy in northern Nigeria (2) and the ex-French territories of west and central Africa were undertaken in the 1960s. In 1967, I surveyed the village of Igabi in northern Nigeria and found that the prevalence of the disease had decreased from 67 per 1000 to 2 per 1000 after 15 years of dapsone monotherapy (3). There were no bacteriological positive patients and so transmission had ceased. Together, with other evidence, it has been possible to conclude that leprosy could be eradicated.

1. Hotez PJ, Velasquez RM, Wolf JE. Neglected tropical skin diseases. Their global elimination through integrated mass drug administration? JAMA 2014; 150 (5): 481-4822.

2. Ross CM. leprosy control programme in in Northern Nigeria. In: Cochrane RG, Davey TF .Eds. Leprosy in theory and practice. Bristol: John Wright. 1964: 595-599.

3. Crawford CL. The effect of out-patient dapsone in an area of endemic leprosy. Lepr Rev 1969; 40 (3): 159-163.

4. Crawford CL. Towards the eradication of leprosy. In: Berhardt LV ed. Adv Med Biol New York: Nova Sci Publ 2012; 56: 117-127.

Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles